A questionnaire on the status of adjuvant therapy after dual HER2-targeted neoadjuvant therapy for patients with early-stage HER2-positive breast cancer from 104 hospitals in China(CSBrS-030)
ZHOU Si-cheng
XIN Ling
JIANG Ze-fei
LIU Yin-hua
Abstract：Objective To investigate the status of adjuvant therapy in patients with early-stage human epidermal growth factor receptor 2(HER2)positive breast cancer in China after dual HER2-targeted neoadjuvant therapy,trastuzumab plus pertuzumab,combined with cytotoxic drugs.Methods The cases of stage Ⅰ-Ⅲ breast cancer treated at 104 hospitals in China between January 1,2023 and December 31,2023 were inquired by a questionnaire survey.The investigation included the number of cases,the proportion of HER2-positive breast cancer,the number of cases of HER2-positive breast cancer receiving dual HER2-targeted neoadjuvant therapy,the evaluation method and results of pathological response after neoadjuvant therapy,and adjuvant therapeutic regimen after neoadjuvant therapy.Results A total of 104 hospitals participated in the questionnaire and provided clinicopathological data of 75 530 patients with early-stage breast cancer,and 7063 patients(40.4％)with HER2-positive breast cancer received neoadjuvant therapy with a dual HER2-targeted regimen.4217 patients(59.7％)achieved pathologic complete response(pCR).The other 2846 patients did not achieved pCR(non-pCR).After dual HER2-targeted neoadjuvant therapy,5658 patients(80.1％)continued dual HER2-targeted adjuvant therapy,360 patients(5.1％)received trastuzumab adjuvant therapy,and 1045 patients(14.8％)received other drugs.There was significant difference between adjuvant targeted therapy in different ypTNM group(x2=1730.058,P＜0.00 1).Conclusion ypTNM stage can provide a basis for formulating follow-up adjuvant therapy regimen for HER2-positive breast cancer patients with non-pCR after dual HER2-targeted neoadjuvant therapy.
Keywords：breast cancerhuman epidermal growth factor receptor 2 positiveneoadjuvant therapydual-targeted therapyadjuvant therapy
Publication Date：2024-11-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 1259-1262 )